Etanercept, a fusion protein of extracellular domain of the TNF-α receptor combined with the Fc portion of the human immunoglobulin molecule, is the first TNF-α antagonist approved for the use in JIA and to date it has proven to be highly efficacious in children with polyarticular JIA [17]. This evidence concerns the gene TNF and juvenile idiopathic arthritis.